Henry Ford Health

Henry Ford Health Scholarly Commons
Gastroenterology Articles

Gastroenterology

8-17-2021

Regulation of Artificial Intelligence-Based Applications in
Gastroenterology
Saurabh Chawla
Jason Schairer
Henry Ford Health, jschair2@hfhs.org

Vladimir Kushnir
Yasmin Genevieve Hernandez-Barco

Follow this and additional works at: https://scholarlycommons.henryford.com/gastroenterology_articles

Recommended Citation
Chawla S, Schairer J, Kushnir V, and Hernandez-Barco YG. Regulation of Artificial Intelligence-Based
Applications in Gastroenterology. Am J Gastroenterol 2021.

This Article is brought to you for free and open access by the Gastroenterology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Gastroenterology Articles by an authorized administrator of Henry
Ford Health Scholarly Commons.

Regulation of Artificial Intelligence-Based
Applications in Gastroenterology
Saurabh Chawla, MD1, Jason Schairer, MD2, Vladimir Kushnir, MD3 and Yasmin Genevieve Hernandez-Barco, MD4; ACG FDA-Related
Matters Committee
Am J Gastroenterol 2021;00:1–4. https://doi.org/10.14309/ajg.0000000000001401; published online August 17, 2021

The advances in artiﬁcial intelligence (AI) and machine
learning (ML) technologies have created an explosion of research
in AI-driven device development in gastroenterology. This is
because machine learning can be reliably trained on and applied
to diagnostic images captured during endoscopy. Recently, several randomized trials evaluating AI and ML for colon polyp
detection have been published. Studies have been conducted
evaluating the role of AI in dysplasia surveillance and other
gastrointestinal (GI) disorders (1).
These technologies pose unique regulatory challenges because
there is no precedent for the US Food and Drug Administration
(FDA) to approve and regulate software which continually evolve
and adapt based on real-world data.
In this article, we summarize the current concepts of the
regulatory framework for medical software-assisted devices. We
hope this would help the readers understand the processes involved before FDA approval for these devices.

EXISTING RISK STRATIFICATION OF DEVICES AND
DEVICE REGULATORY PATHWAYS
A device is described as an instrument, reagent, or similar
intended to diagnose or treat a disease or condition which does
not fall under drug or biologics categories within the FDA (2).
Medical devices are categorized in 3 classes (class I–III) based on
the degree of risk they present. Class I devices are those that
present minimal potential for harm (e.g., bandages and tongue
depressors), whereas class III devices are those that are critical for
sustaining or supporting life and/or present potential risk of illness or injury (e.g., pacemakers).
Based on the risk classiﬁcation of the device, the intended use,
and the presence of similar approved devices in the market, the
device is then submitted to the FDA for approval, through 1 of 4
pathways (Table 1).
SOFTWARE AS A MEDICAL DEVICE
Software has become an integral part of most medical devices.
Software can be used for manufacture or maintenance of a medical
device (e.g., built-in diagnostic software which detects errors in
machine operation) or can be integral for device functioning (also
known as software in medical device [SiMD]). SiMD are part of the
device hardware and are not regulated independently by the FDA.
In 2013, the International Medical Device Regulators Forum, under the leadership of the FDA, deﬁned a third category of medical

device software as “software as a medical device (SaMD)” (3)
(Figure 1). SaMD is intended to be used for 1 or more medical
purposes without being part of a hardware medical device. These
medical software are now ubiquitous and have functions ranging
from delivering consolidated data output to inﬂuencing management decisions and are used in a large range of healthcare situations. Based on their role in decision-making and the impact of the
software guidance, the FDA stratiﬁes SaMD into 4 categories.
Devices deemed to aﬀect serious or critical health conditions are
recommended to undergo independent review, whereas the lower
category devices can be approved based on manufacturer’s “selfdeclaration” (4) (Figure 2). A key tenant of conventional SaMDs
has been the “locked algorithm” (Figure 3).
Locked algorithms provide the same result each time the same
input is applied and does not change with use (4).
In these devices, the manufacturer can leverage the connectivity of the SaMD to monitor the safety, eﬀectiveness, and the
performance of SaMD. Any change in the algorithms require
revalidation of the SaMD and resubmission for approval to the
FDA. International Medical Device Regulators Forum and the
FDA have outlined a pathway based on organization-based total
product lifecycle approach, which would help streamline software
precertiﬁcation. It allows software regulation across its lifecycle
from design and development to postmarket surveillance and
software changes while monitoring the social-technical and information safety environment for the software (5). The FDA’s
Center for Devices and Radiological Health has also published
guidance on approval for software changes to existing devices
based on the risk to users or patients (4).

AI/ML BASED SAMD
There have been considerable recent advances in medical software development based on the concepts of AI and ML (6).
The FDA has approved several AI/ML-based SaMD with
locked algorithms and changes beyond original market authorization requiring FDA premarket review. The FDA recognizes that
the transformative potential of AI/ML-based SaMD is adaptive
and can constantly evolve from real-world use and experience,
leading to improved performance and expanded indications. It
acknowledges that the current paradigm for medical device regulation was not designed for adaptive AI/ML technologies and
has been developing a framework to provide appropriate regulatory oversight (7).
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Table 1. Different pathways utilized by US Food and Drug Administration for device approval
510(k) (premarket notification)

Used when submitted new device is “substantially equivalent”
to a predicate device in terms of intended use, technological
characteristics, and performance testing, as needed

Usually for class II and some class I devices.
Important to note that most class I and some
class II devices may be exempt from premarket
submission

De novo classification request

Pathway to classify novel medical devices for which there are
no similar approved devices but there exists general or specific
control data demonstrating safety and effectiveness

Used for class I–III devices

Premarket approval (PMA)

Most stringent approval process, where the sponsor must
provide high quality scientific evidence of the device’s safety
and efficacy

Usually used for class III devices

Humanitarian device exemption (HDE)

Pathway for approval of class III devices which are intended to
benefit patients with rare diseases or conditions and do not
have robust scientific evidence for support

Usually reserved for class III devices and
require the device to be designated as
Humanitarian Use Device (HUD) prior to
submission

In April 2019, it published the discussion article “Proposed
Regulatory Framework for Modiﬁcations to AI/ML-Based
SaMD” and requested public feedback (7).This framework proposed a new total product lifecycle approach that would allow
regulatory oversight while allowing for iterative improvement in
the AI/ML-based SaMD and ensuring patient safety. The key
components of this approach were as follows:
1. Establish clear expectations on quality systems and good ML
practices from the device manufacturers to have assurance on
their software development, testing, and performance monitoring
throughout the lifecycle of the product.
2. Develop a predetermined change control plan to include
anticipated modiﬁcations—SaMD Prespeciﬁcations based on
retraining and model update strategy and Algorithm Change
Protocol—used to implement changes in a controlled fashion,

which would determine need for regulatory approval of
changes to the AI/ML-based SaMD.
3. Establish mechanisms that support transparency and realworld performance monitoring of these devices and allow the
FDA to evaluate the product from premarket development
through postmarket performance.
In a subsequent patient advisory committee meeting various
concerns and limitations related to AI/ML technology such as generalizability and external validity of training data, algorithmic biases
and opacity of data processing (also known as “black box” of AI),
trustworthiness, consent, and skills degradation were discussed (8).
Based on the feedback from various stakeholders, the FDA released an AI/ML-based SaMD Action Plan in January 2021. It
highlights steps to improve the regulatory plan for these devices
(9). These include:

Figure 1. Definition and classification of traditional and software based medical devices. Source: FDA (8). FDA, US Food and Drug Administration; SaMD,
software as a medical device.
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Figure 2. Framework for evaluation of software as a medical device (SaMD) for independent review. Categories I–IV are stratification of SaMD devices based
on their healthcare impact from low to critical. Levels i–iii are risk stratification within each category from low to highest risk. Source: FDA (4). FDA, US Food
and Drug Administration.

1. Issue a draft guidance on the Predetermined Change
Control Plan to allow for modiﬁcations to AI/ML-based
SaMD.
2. Develop consensus outcomes for good ML practices by
collaborating with key stakeholders in the community,
industry, and other regulatory bodies.
3. Hold a public workshop on device labelling to support
transparency and enhance trust in AI/ML-based devices.
4. Recognize the risk of bias and generalizability because of
limited training sets for AI/ML algorithms and support
regulatory science eﬀorts to develop methodology for the
evaluation and improvement of ML algorithms.
5. Coordinate with stakeholders and other FDA programs to
support pilot projects of real-world performance monitoring
and its impact on AI/ML-based SaMD.

CASE STUDY
The FDA recently approved GI Genius, a AI/ML-based SaMD,
which aids in polyp detection (10). This SaMD uses ML-based
algorithms to identify and highlight polyps to aid the endoscopist in real time during a colonoscopy. Notably, this device
has been studied as an aid in polyp detection and not in polyp
characterization in a randomized clinical trial. It is not intended
to guide the clinician in clinical management. Given its role as a
diagnostic aid, this SaMD was deemed low to moderate risk by
the FDA and approved through the De Novo classiﬁcation
pathway because there is no legally marketed predicate device to
which this device can claim substantial equivalence. After this
approval, subsequent generations of AI/ML SaMD for similar
use could go through 510 (k) pathway if they demonstrated
equivalence to this predicate device.

Figure 3. Basic programming model for a locked algorithm SaMD. Source: FDA (4). FDA, US Food and Drug Administration.
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APPLICATIONS FOR GASTROENTEROLOGY
At the time of submission of this manuscript several diagnostic GI
AI/ML SaMD are being developed and undergoing rigorous
clinical testing (1). These include AI/ML SaMD for classifying
severity of colitis, detection of GI bleeding, detection of dysplasia
etc. Most of these devices would be classiﬁed as diagnostic assist
devices which would require the gastroenterologist to review the
software generated alerts, and may therefore fall into the lowmoderate risk category. These initial devices could be reviewed
through De Novo classiﬁcation with subsequent iterations being
approved through the 510 (k) pathway (4).
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